AVANT Immunotherapeutics Inc. (Nasdaq: AVAN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AVANT Immunotherapeutics Inc. (Nasdaq: AVAN)

AVAN 10.04

0.0%

Jun 12 9:41 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: rrufff who wrote (496)	7/17/2004 7:22:30 PM
From: tom pope	Read Replies (1) of 513

obscure firms now getting noticed And: "BioShield is supposed to send a clear signal to the capital markets that this is its own sector," said Richard Hollis, chairman and chief executive of Hollis-Eden Pharmaceuticals (HEPH: news, chart, profile). Hollis-Eden is expected to be one of the first companies to benefit from the bill Not to be cynical, but HEPH's price - a double in just over two months - might indicate it was noticed at least a little while ago. stockcharts.com[w,a]daclyiay[dc][pb50!b200!f][vc60][iUh14,3!La12,26,9]&pref=G

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next